跳转至内容
Merck
CN

B7431

苔藓抑素1

≥99%, Protein kinase C activator, solid

别名:

NSC 339555

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C47H68O17
化学文摘社编号:
83314-01-6
分子量:
905.03
UNSPSC Code:
12352200
PubChem Substance ID:
24891991
NACRES:
NA.77
MDL number:
MFCD00893832
Assay:
≥99%
Form:
solid
Quality level:
100

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

苔藓抑素1, ≥99%, solid

SMILES string

[H]\C(C(=O)OC)=C1/C[C@@]2([H])C[C@]3(O)O[C@]([H])(C[C@@H](O)CC(=O)O[C@H](C[C@]4([H])C\C(=C(\[H])C(=O)OC)[C@H](OC(=O)\C=C\C=C\CCC)[C@@](O)(O4)C(C)(C)\C=C\[C@@]([H])(C1)O2)[C@@H](C)O)C[C@H](OC(C)=O)C3(C)C

InChI key

MJQUEDHRCUIRLF-TVIXENOKSA-N

InChI

1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1

assay

≥99%

form

solid

color

white

solubility

DMSO: soluble, ethanol: soluble

storage temp.

−20°C

Quality Level

100

相关类别

Application

苔藓虫素1已用于研究其对小鼠结肠炎等自发性克罗恩病′（CD）的影响。它也已用于研究其作为驱虫药对大鼠中成年鼠管线虫感染的影响。

Biochem/physiol Actions

从海洋苔藓虫 Bugula neritina 中分离的大环内酯可首先激活并随后下调蛋白激酶C（PKC）。其转移PKCδ 和ε的效果比佛波醇肉豆蔻酸乙酸酯更好。
苔藓虫素(Bry1)是一种大环内酯。这种突触发生性化合物是从海洋苔藓虫多室草苔虫中获得的。Bry1能够逆转突触损失。它可以促进多种神经系统疾病动物模型中的突触成熟。当用于脑室给药时，它具有抗抑郁活性。现已确知Bry1参与保护细胞紧密连接（TJ）、抗炎功能和免疫调节。

Other Notes

与水溶液中的玻璃和塑料结合

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
MKCZ6729
MKCZ6728
MKCX7100
MKCV6265
MKCW8251

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Moisés Pérez et al.
Current HIV research, 8(6), 418-429 (2010-07-20)
The persistence of latent HIV-infected cellular reservoirs represents the major hurdle to virus eradication on patients treated with HAART. It has been suggested that successful depletion of such latent reservoirs will require a combination of therapeutic agents that can specifically
B Douglas Smith et al.
Leukemia research, 35(1), 87-94 (2010-07-06)
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth
Jarin Hongpaisan et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 31(2), 630-643 (2011-01-14)
Among the pathologic hallmarks of Alzheimer's disease (AD) neurodegeneration, only synaptic loss in the brains of AD patients closely correlates with the degree of dementia in vivo. Here, we describe a molecular basis for this AD loss of synapses: pathological
Maria Eugenia Ariza et al.
The Journal of biological chemistry, 286(1), 24-34 (2010-11-03)
Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (in
Bryostatin-1 ameliorated experimental colitis in Il-10-/- Mice by protecting the intestinal barrier and limiting immune dysfunction
Zuo L, et al.
Journal of Cellular and Molecular Medicine, 23(8), 5588-5599 (2019)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持